Skip to main content
. 2021 Oct 23;117:47–56. doi: 10.1016/j.placenta.2021.10.012

Fig. 5.

Fig. 5

(a) Granular positive immunoreactivity with anti-spike antibody in the positive control pelet prepared from SARS-CoV2 infected Vero E6 cells (×20), (b) there is no positive immunoreactivity in negative control pellet with Anti-Spike antibody, which is prepared from non-infected Vero E6 cells (×20), (c) negative immunoreactivity in the negative control pellet which is prepared from SARS-CoV-2 infected Vero E6 cells and incubated with the diluent (PBS) instead of Anti-Spike antibody and then with secondary antibody.